TAG fact sheet: Broadly neutralizing antibodies (bNAbs) and HIV cure-related research

Back to the "HIV and Co-Infections News" list

HIV has evolved multiple mechanisms to evade inhibition by antibodies, which are Y-shaped immune system proteins that normally play a key role in fending off or controlling infections. Most antibodies that the immune system generates against HIV are ineffective and cannot block infection or viral replication. Over the past decade or so, technological advances have allowed researchers to identify rare antibodies that have very strong anti-HIV activity against multiple viral variants from around the world. These antibodies are categorized as broadly neutralizing antibodies (bNAbs). Many different bNAbs are now being manufactured to allow for testing in clinical trials as candidate HIV treatments, preventive agents, and in the context of cure-related research.

Treatment Action Group (TAG)’s July 2023 fact sheet provides an update on research into bNAbs by scientists pursuing the development of an HIV cure.

Access the fact sheet here.


Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?


Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.